NASDAQ:ELEV
Elevation Oncology, Inc. Stock Company Profile
$3.82
-0.180 (-4.50%)
At Close: May 02, 2024
Information
888 Seventh Avenue, 12th Floor
New York NY 10106
716 371 1125
elevationoncology.com
Industry: Biotechnology
Sector: Healthcare
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
